– SWITZERLAND, Lugano – Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that Jeffrey Riley joined Gain Therapeutics as Independent Board Member.
“We are delighted to have Jeff join us as an independent board member,” said Dr. Khalid Islam, Chairman of the Board of Gain Therapeutics SA. “Jeff’s perspective, based on his distinguished career and leadership roles in R&D organizations and his transactional expertise will be very valuable to the board as the company seeks to execute on its global product discovery and development strategy.”
About Jeffrey Riley
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma, venture capital and numerous biotechnology companies in his capacity of business development and general management.
“I am delighted to join Gain Therapeutics and support its endeavours to bring to patients brain penetrant small molecule able to regulate misfolded enzymes involved in rare pediatric diseases and in neurodegenerative disease for which high unmet medical needs still exist,” said Jeffrey Riley.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
For more information: https://www.gaintherapeutics.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.